 BOSTON--BUSINESS WIRE--Aura Biosciences, Inc. NASDAQ: AURA, a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate VDC therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal SC administration using its first VDC product candidate, belzupacap sarotalocan AU-011, for the first-line treatment of patients with early-stage choroidal melanoma indetermina 